Berkshire Hills Announces Quarterly Shareholder Dividend

(Neutral)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

dividends

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

03/07/2024 - 04:30 PM

BOSTON, March 7, 2024 /PRNewswire/ -- Berkshire Hills Bancorp, Inc. (NYSE: BHLB) today announced that its Board of Directors has approved a quarterly cash dividend of $0.18 per common share to shareholders of record at the close of business on March 21, 2024, payable on April 4, 2024.

About Berkshire Hills Bancorp

Headquartered in Boston, Berkshire Hills Bancorp is the parent of Berkshire Bank. With $12.4 billion in assets and 96 branches in New England and New York, the Bank provides Commercial Banking, Retail Banking, Consumer Lending, Private Banking and Wealth Management services. Access more information about Berkshire Hills Bancorp at ir.berkshirebank.com.

Investor Relations Contact

Kevin Conn, Senior Managing Director, Investor Relations & Corporate Development
Email: KAConn@berkshirebank.com
Tel: (617) 641-9206

View original content to download multimedia:https://www.prnewswire.com/news-releases/berkshire-hills-announces-quarterly-shareholder-dividend-302081749.html

SOURCE Berkshire Hills Bancorp, Inc.

Keep reading

More on BHLB

Aug 25, 2025 Berkshire Hills Bancorp and Brookline Bancorp Receive Regulatory Approvals for Merger of Equals to form Beacon Financial Corporation
Aug 1, 2025 Berkshire Hills Announces Quarterly Shareholder Dividend
Jul 24, 2025 Berkshire Hills Reports Strong Earnings Growth

All BHLB news

Trending in the feed

PCVX

Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate Open the live feed